by Peter Ciszewski | Jun 17, 2020
The U.S. Food and Drug Administration (FDA) has approved Ilaris (canakinumab) to treat Still’s disease. Still’s disease is a rare autoinflammatory disease of unknown origin. It is similar to systemic juvenile idiopathic arthritis (SJIA), another rare autoimmune...
by Peter Ciszewski | Jun 16, 2020
Ozlem Goker-Alpan, MD provides a summary of research presented at WORLDSymposium 2020 focused on the pain associated with Fabry disease. Fabry disease an X-linked genetic disorder that leads to the buildup of globotriaosylceramide in the body’s cells that can...
by Peter Ciszewski | Jun 15, 2020
Riam Shammaa, MD, Founder and CEO of INTELLiSTEM Technologies, talks about the some of the vaccines in development targeting the coronavirus. As Dr. Shammaa explains in this video, numerous companies are likely needed to develop multiple vaccines to make sure...
by Peter Ciszewski | Jun 12, 2020
The US Food and Drug Administration (FDA) has approved Uplizna (inebilizumab-cdon) to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive. NMOSD is a rare autoimmune disease of the central nervous system...
by Peter Ciszewski | Jun 10, 2020
Bettina Cockcroft, MD, Chief Medical Officer at Sangamo Therapeutics, recently talked to CheckRare about the gene therapy that the company has in development to treat people with Fabry disease. Fabry disease is a rare lysosomal storage disorder involving mutations of...
